Hansoh Pharmaceutical Group Company Limited

announcement INSIDE INFORMATION - STRATEGIC COLLABORATION AND LICENSE AGREEMENT WITH ROCHE HKEXPDF 19. říj 2026 před 9 dny announcement VOLUNTARY ANNOUNCEMENT - MARKETING AUTHORIZATION APPLICATION OF AUMOLERTINIB IN THE EU RESUBMITTED AND VALIDATED BY THE EMA HKEXPDF 11. říj 2026 před 17 dny announcement Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026 HKEXPDF 2. říj 2026 před 26 dny announcement VOLUNTARY ANNOUNCEMENT - UPDATE ON THE MARKETING AUTHORIZATION STATUS OF AUMOLERTINIB IN THE EU HKEXPDF 27. zář 2026 před 1 měs. announcement VOLUNTARY ANNOUNCEMENT - BIOLOGICS LICENSE APPLICATION OF RISVUTATUG REZETECAN FOR INJECTION (HS-20093) FOR OSTEOSARCOMA ACCEPTED BY THE NMPA HKEXPDF 24. zář 2026 před 1 měs. announcement NOTIFICATION LETTER TO NON-REGISTERED HOLDERS AND REQUEST FORM HKEXPDF 23. zář 2026 před 1 měs. announcement NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM HKEXPDF 23. zář 2026 před 1 měs. interim_report INTERIM REPORT 2026 HKEXPDF 23. zář 2026 před 1 měs. announcement VOLUNTARY ANNOUNCEMENT - RISVUTATUG REZETECAN FOR INJECTION (HS-20093) FOR OSTEOSARCOMA INCLUDED IN PRIORITY REVIEW AND APPROVAL PROCEDURE OF THE NMPA HKEXPDF 22. zář 2026 před 1 měs. announcement VOLUNTARY ANNOUNCEMENT - THE PHASE III CLINICAL STUDY OF HS-10374 IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS HAS MET THE CO-PRIMARY ENDPOINTS HKEXPDF 21. zář 2026 před 1 měs. announcement VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-20197 FOR INJECTION ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 16. zář 2026 před 1 měs. announcement VOLUNTARY ANNOUNCEMENT - RISVUTATUG REZETECAN FOR INJECTION (HS-20093) FOR SMALL CELL LUNG CANCER INCLUDED IN PRIORITY REVIEW AND APPROVAL PROCEDURE OF THE NMPA HKEXPDF 11. zář 2026 před 2 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2026 HKEXPDF 3. zář 2026 před 2 měs. announcement VOLUNTARY ANNOUNCEMENT - BIOLOGICS LICENSE APPLICATION OF HS-20093 FOR INJECTION FOR SMALL CELL LUNG CANCER ACCEPTED BY THE NMPA HKEXPDF 2. zář 2026 před 2 měs. announcement ADJUSTMENT TO CONVERSION PRICE OF THE CONVERTIBLE BONDS HKEXPDF 26. srp 2026 před 2 měs. announcement INTERIM DIVIDEND FOR THE SIX MONTHS ENDED JUNE 30, 2026 HKEXPDF 26. srp 2026 před 2 měs. interim_report INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 HKEXPDF 26. srp 2026 před 2 měs. announcement VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-10582 TABLETS ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 6. srp 2026 před 3 měs. announcement DATE OF BOARD MEETING HKEXPDF 4. srp 2026 před 3 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2026 HKEXPDF 4. srp 2026 před 3 měs. announcement VOLUNTARY ANNOUNCEMENT - THE PHASE III CLINICAL STUDY OF HS-20093 IN THE TREATMENT OF OSTEOSARCOMA HAS MET THE PRIMARY ENDPOINT HKEXPDF 28. čvc 2026 před 3 měs. announcement VOLUNTARY ANNOUNCEMENT - TRANSACTIONS WITH AVERE THERAPEUTICS HKEXPDF 14. čvc 2026 před 3 měs. announcement VOLUNTARY ANNOUNCEMENT - THE PHASE III CLINICAL STUDY OF HS-20093 IN THE TREATMENT OF SMALL CELL LUNG CANCER HAS MET THE PRIMARY ENDPOINT HKEXPDF 10. čvc 2026 před 4 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2026 HKEXPDF 3. čvc 2026 před 4 měs. announcement VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVALS FOR HS-20136-2 INJECTION ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 2. čvc 2026 před 4 měs. results_announcement POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON FRIDAY, JUNE 26, 2026 HKEXPDF 26. čvn 2026 před 4 měs. announcement VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION OF HS-10568 INJECTION WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 10. čvn 2026 před 5 měs. announcement CHANGE OF JOINT COMPANY SECRETARY HKEXPDF 10. čvn 2026 před 5 měs. announcement 2026 SHARE SCHEME HKEXHTML 4. čvn 2026 před 5 měs. announcement NOTIFICATION LETTER TO NON-REGISTERED HOLDERS AND REQUEST FORM HKEXPDF 4. čvn 2026 před 5 měs. announcement NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM HKEXPDF 4. čvn 2026 před 5 měs. announcement FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 26, 2026 HKEXPDF 4. čvn 2026 před 5 měs. announcement NOTICE OF ANNUAL GENERAL MEETING HKEXPDF 4. čvn 2026 před 5 měs. announcement (1) PROPOSED RE-ELECTION OF DIRECTORS, (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES, (3) PROPOSED DECLARATION OF FINAL DIVIDEND, (4) PROPOSED RE-APPOINTMENT OF AUDITORS, (5) PROPOSED ADOPTION OF THE 2026 SHARE SCHEME AND (6) NOTICE OF ANNUAL GENERAL MEETING HKEXPDF 4. čvn 2026 před 5 měs. announcement VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION OF OLATOREPATIDE INJECTION WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 4. čvn 2026 před 5 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2026 HKEXPDF 2. čvn 2026 před 5 měs. announcement VOLUNTARY ANNOUNCEMENT - THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR FOURTH-GENERATION EGFR-TKI HS-10504 TABLETS FOR NSCLC HKEXPDF 21. kvě 2026 před 5 měs. announcement CHANGES OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT HKEXPDF 15. kvě 2026 před 5 měs. announcement VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-10541 TABLETS ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 13. kvě 2026 před 6 měs. announcement VOLUNTARY ANNOUNCEMENT - THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA HKEXPDF 11. kvě 2026 před 6 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026 HKEXPDF 4. kvě 2026 před 6 měs. announcement VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE RESTRICTED SHARE UNIT SCHEME HKEXPDF 30. dub 2026 před 6 měs. announcement VOLUNTARY ANNOUNCEMENT - THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 FOR CASTRATION-RESISTANT PROSTATE CANCER HKEXPDF 29. dub 2026 před 6 měs. announcement VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVALS FOR HS-10522 TABLETS ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 29. dub 2026 před 6 měs. announcement VOLUNTARY ANNOUNCEMENT - NOVATION AND TRANSFER AGREEMENTS HKEXPDF 29. dub 2026 před 6 měs. announcement TERMINATION OF THE POST-IPO RSU SCHEME AND PROPOSED ADOPTION OF THE 2026 SHARE SCHEME HKEXPDF 28. dub 2026 před 6 měs. announcement GRANT OF RESTRICTED SHARE UNITS UNDER THE POST-IPO RSU SCHEME HKEXPDF 28. dub 2026 před 6 měs. announcement FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2025 (UPDATED) HKEXPDF 28. dub 2026 před 6 měs. announcement NOTIFICATION LETTER TO NON-REGISTERED HOLDERS AND REQUEST FORM HKEXPDF 28. dub 2026 před 6 měs. announcement NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM HKEXPDF 28. dub 2026 před 6 měs. esg_report ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025 HKEXPDF 28. dub 2026 před 6 měs. Výroční ANNUAL REPORT 2025 HKEXPDF 28. dub 2026 před 6 měs. announcement Next Day Disclosure Return HKEXPDF 17. dub 2026 před 6 měs. announcement VOLUNTARY ANNOUNCEMENT - THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 IN COMBINATION WITH ADEBRELIMAB HKEXPDF 16. dub 2026 před 6 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026 HKEXPDF 2. dub 2026 před 7 měs. announcement FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2025 HKEXPDF 29. bře 2026 před 7 měs. Výroční ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 HKEXPDF 29. bře 2026 před 7 měs. announcement VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE THIRD INDICATION OF XINYUE (INEBILIZUMAB INJECTION) WAS GRANTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 27. bře 2026 před 7 měs. announcement VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-20152 INJECTION ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 23. bře 2026 před 7 měs. announcement VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-10587 TABLETS ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 23. bře 2026 před 7 měs. announcement DATE OF BOARD MEETING HKEXPDF 18. bře 2026 před 7 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026 HKEXPDF 2. bře 2026 před 8 měs. announcement VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION OF DALMELITINIB MESYLATE TABLETS WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 27. úno 2026 před 8 měs. announcement VOLUNTARY ANNOUNCEMENT - AUMOLERTINIB MESYLATE TABLETS WAS APPROVED IN THE EU AS MONOTHERAPY HKEXPDF 20. úno 2026 před 8 měs. announcement COMPLETION OF THE ISSUE OF HK$4,680 MILLION ZERO COUPON CONVERTIBLE BONDS DUE 2033 HKEXPDF 3. úno 2026 před 9 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026 HKEXPDF 3. úno 2026 před 9 měs. announcement PROPOSED ISSUE OF HK$4,680 MILLION ZERO COUPON CONVERTIBLE BONDS DUE 2033 HKEXPDF 27. led 2026 před 9 měs. announcement VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE FIFTH INDICATION OF AMEILE (AUMOLERTINIB MESYLATE TABLETS) WAS GRANTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 8. led 2026 před 10 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025 HKEXPDF 5. led 2026 před 10 měs. announcement LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS HKEXPDF 28. pro 2025 před 10 měs. announcement (1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR; (2) CHANGE IN COMPOSITION OF BOARD COMMITTEES; AND (3) CHANGES OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT HKEXPDF 28. pro 2025 před 10 měs. announcement VOLUNTARY ANNOUNCEMENT - LICENSE AGREEMENT WITH HENGRUI HKEXPDF 28. pro 2025 před 10 měs. announcement VOLUNTARY ANNOUNCEMENT - LICENSE AGREEMENT WITH GLENMARK HKEXPDF 16. pro 2025 před 10 měs. announcement VOLUNTARY ANNOUNCEMENT - PROGRESS ON THE INCLUSION OF INNOVATIVE DRUGS IN THE 2025 NATIONAL REIMBURSEMENT DRUG LIST HKEXPDF 8. pro 2025 před 11 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025 HKEXPDF 2. pro 2025 před 11 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025 HKEXPDF 3. lis 2025 před 1 r. announcement VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION OF HS-10365 CAPSULES WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 23. říj 2025 před 1 r. announcement INSIDE INFORMATION - LICENSE AGREEMENT WITH ROCHE HKEXPDF 17. říj 2025 před 1 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025 HKEXPDF 2. říj 2025 před 1 r. announcement INTERIM DIVIDEND FOR THE SIX MONTHS ENDED JUNE 30, 2025 (UPDATED) HKEXPDF 23. zář 2025 před 1 r. announcement RESCHEDULE OF DATES FOR INTERIM DIVIDEND FOR THE SIX MONTHS ENDED JUNE 30, 2025 DUE TO WEATHER CONDITIONS HKEXPDF 23. zář 2025 před 1 r. announcement NOTIFICATION LETTER TO NON-REGISTERED HOLDERS AND REQUEST FORM HKEXPDF 22. zář 2025 před 1 r. announcement NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM HKEXPDF 22. zář 2025 před 1 r. interim_report INTERIM REPORT 2025 HKEXPDF 22. zář 2025 před 1 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2025 HKEXPDF 2. zář 2025 před 1 r. announcement VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE SECOND INDICATION OF XINYUE (INEBILIZUMAB INJECTION) WAS GRANTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 1. zář 2025 před 1 r. announcement Next Day Disclosure Return HKEXPDF 27. srp 2025 před 1 r. announcement PLACING OF NEW SHARES UNDER GENERAL MANDATE ON FULLY UNDERWRITTEN BASIS HKEXPDF 20. srp 2025 před 1 r. announcement ADJUSTMENT TO CONVERSION PRICE OF THE CONVERTIBLE BONDS HKEXPDF 18. srp 2025 před 1 r. announcement INTERIM DIVIDEND FOR THE SIX MONTHS ENDED JUNE 30, 2025 HKEXPDF 18. srp 2025 před 1 r. interim_report INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 HKEXPDF 18. srp 2025 před 1 r. announcement DATE OF BOARD MEETING HKEXPDF 6. srp 2025 před 1 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2025 HKEXPDF 4. srp 2025 před 1 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2025 HKEXPDF 2. čvc 2025 před 1 r. results_announcement POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON FRIDAY, JUNE 20, 2025 HKEXPDF 20. čvn 2025 před 1 r. announcement VOLUNTARY ANNOUNCEMENT - AUMOLERTINIB MESILATE TABLETS WAS APPROVED BY THE MHRA FOR MARKETING HKEXPDF 4. čvn 2025 před 1 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2025 HKEXPDF 3. čvn 2025 před 1 r. announcement INSIDE INFORMATION - LICENSE AGREEMENT WITH REGENERON HKEXPDF 2. čvn 2025 před 1 r. announcement VOLUNTARY ANNOUNCEMENT - THE THIRD BIOLOGICS LICENSE APPLICATION OF XINYUE (INEBILIZUMAB INJECTION) WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 30. kvě 2025 před 1 r. announcement NOTIFICATION LETTER TO NON-REGISTERED HOLDERS AND REQUEST FORM HKEXPDF 29. kvě 2025 před 1 r. announcement NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM HKEXPDF 29. kvě 2025 před 1 r. announcement FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 20, 2025 HKEXPDF 29. kvě 2025 před 1 r. announcement NOTICE OF ANNUAL GENERAL MEETING HKEXPDF 29. kvě 2025 před 1 r. announcement (1) PROPOSED RE-ELECTION OF DIRECTORS, (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES, (3) PROPOSED DECLARATION OF FINAL DIVIDEND, (4) PROPOSED RE-APPOINTMENT OF AUDITORS AND (5) NOTICE OF ANNUAL GENERAL MEETING HKEXPDF 29. kvě 2025 před 1 r. announcement VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-10510 TABLETS ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 29. kvě 2025 před 1 r. announcement VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-10542 CAPSULES ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 29. kvě 2025 před 1 r. announcement VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-20118 TABLETS ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 29. kvě 2025 před 1 r. announcement VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE FOURTH INDICATION OF AMEILE (AUMOLERTINIB MESILATE TABLETS) WAS GRANTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 9. kvě 2025 před 1 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2025 HKEXPDF 2. kvě 2025 před 1 r. announcement VOLUNTARY ANNOUNCEMENT - THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H4-TARGETED ANTIBODY-DRUG CONJUGATE HS-20089 HKEXPDF 1. kvě 2025 před 1 r. announcement GRANT OF RESTRICTED SHARE UNITS UNDER THE POST-IPO RSU SCHEME HKEXPDF 28. dub 2025 před 1 r. announcement FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2024 (UPDATED) HKEXPDF 28. dub 2025 před 1 r. announcement NOTIFICATION LETTER TO NON-REGISTERED HOLDERS AND REQUEST FORM HKEXPDF 28. dub 2025 před 1 r. announcement NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM HKEXPDF 28. dub 2025 před 2 r. esg_report ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2024 HKEXPDF 28. dub 2025 před 2 r. Výroční ANNUAL REPORT 2024 HKEXPDF 28. dub 2025 před 2 r. announcement VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF HENGMEIDA (IBREXAFUNGERP TABLETS) WAS GRANTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 25. dub 2025 před 2 r. announcement Next Day Disclosure Return HKEXPDF 22. dub 2025 před 2 r. announcement VOLUNTARY ANNOUNCEMENT - THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 FOR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER HKEXPDF 17. dub 2025 před 2 r. announcement VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-10529 TABLETS ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION HKEXPDF 15. dub 2025 před 2 r.